Transition fully enrolled for gastrin analog trial

Canada's Transition Therapeutics has completed patient enrolment for a Phase II study of its gastrin analog, TT-223, in patients with type 2  diabetes.

The study is a randomized, double-blind, placebo-controlled,  dose-ranging trial to evaluate the safety, tolerability and efficacy of  daily TT-223 treatments for 12 weeks with a six-month follow-up.  Approximately 80 patients with type 2 diabetes have been enrolled in the  study. Patients receive a daily treatment of TT-223 in addition to their  current regimen of oral glucose lowering agents (metformin and/or  thiazolidinediones).

Transition has entered into a licensing and collaboration agreement  granting Eli Lilly exclusive worldwide rights to develop and  commercialize gastrin-based therapies, including TT-223. The drugs are  an emerging class of potential disease-modifying therapies for patients  with diabetes, and have been shown to provide sustained improvement in  glycemic control in preclinical models and early clinical studies.